An Observational Cohort Study in Patients With Chronic Hepatitis B Receiving Pegasys
- Conditions
- Hepatitis B, Chronic
- Registration Number
- NCT01011738
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This observational, non-interventional cohort study will evaluate predictors of response in patients with chronic hepatitis B receiving standard of care Pegasys therapy. Efficacy and safety parameters will also be evaluated. Patients included in the study will be followed for the duration of their treatment and for up to 3 years thereafter.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1842
- adult patient, >/= 18 years of age
- chronic hepatitis B
- treatment with peginterferon alfa-2A
- coinfection with HAV, HCV and HIV
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of Participants With Hepatitis B Virus Surface Antigen Clearance Up to 276 Weeks Percentage of participants who became Hepatitis B Virus Surface Antigen (HBsAg) negative by the end of the observation period. A participant was considered to have achieved HBsAg clearance if the HBsAg measurement was reported as: (a) 'Negative' or (b) a quantitative result lower than the reported lower limit of detection. An observational period was upto 3 years post-treatment. The analysis was performed by 2 methods: Analysis A and Analysis B. For analysis A, all participants included in the analyzed population were used (participants with missing measurement for calculation of the endpoint were considered non-responders regarding the endpoint). For analysis B method, only participants in the analyzed population without missing measurements for calculation of the endpoint were used (analysis "as observed").
Predictive Values of Early on Treatment Response for Hepatitis B Surface Antigen Clearance 3 Years Post-Treatment- Hepatitis B Virus e Antigen Positive Participants Up to 276 Weeks The probability that the participant who develops an early virological/serological response would achieve Hepatitis B Surface Antigen (HBsAg) clearance 3 years post-treatment is called the positive predictive value (PPV) of the early virological/serological response. The probability that the participant who fails to develop an early virological/serological response also would fail to achieve HBsAg clearance 3 years post-treatment is called the negative predictive value (NPV) of the early virological/serological response. The positive and negative predictive values of early response at Weeks 12 and 24 on achievement of HBsAg clearance at 3 years post-treatment were examined. The following evidence of early response was explored (giving both NPV and PPV): For HBeAg positive participant, HBsAg \<1,500 International Units Per Milliliter (IU/mL) and HBsAg \<20,000 IU/mL at Weeks 12 and 24.
Predictive Values of Early on Treatment Response for Hepatitis B Surface Antigen Clearance 3 Years Post-Treatment- Hepatitis B Virus e Antigen Negative Participants Up to 276 Weeks The probability that the participant who develops an early virological/serological response would achieve HBsAg clearance 3 years post-treatment is called the PPV of the early virological/serological response. The probability that the participant who fails to develop an early virological/serological response also would fail to achieve HBsAg clearance 3 years post-treatment is called the NPV of the early virological/serological response. The positive and negative predictive values of early response at Weeks 12 and 24 on achievement of HBsAg clearance at 3 years post-treatment were examined. The following evidence of early response was explored (giving both NPV and PPV): For HBeAg negative patients, any decline in HBsAg from baseline to Week 12 and 24 and at least a 10% decline in HBsAg from baseline to Weeks 12 and 24.
- Secondary Outcome Measures
Name Time Method Number of Participants With Non-Serious Adverse Drug Reactions Up to 276 Weeks Non serious adverse drug reactions (NSADRs) are all noxious and unintended responses to a medicinal product related to any dose.
Percentage of Participants With Hepatitis B Virus e Antigen Seroconversion in Hepatitis B Virus e Antigen Positive Participants Up to 276 Weeks HBeAg seroconversion is presented as percentage of participants who become HBeAg negative and anti-HBe positive. A participant was considered to have achieved HBeAg seroconversion if (a) the participant achieved HBeAg loss and (b) the anti-HBe measurement was reported as (i) 'POSITIVE' or (ii) a quantitative result considered 'positive' in the context. HBeAg seroconversion and suppression of HBV DNA to \<2,000 IU/mL: A participant was considered to have achieved HBeAg seroconversion and suppression of HBV DNA to \<2,000 IU/mL if (a) the participant achieved HBeAg seroconversion and (b) the participant achieved suppression of HBV DNA to \<2,000 IU/mL.
Abbreviations for pt=post-treatment.Percentage of Participants With Hepatitis B Virus e Antigen Loss in Hepatitis B Virus e Antigen Positive Participants Up to 276 Weeks A participant was considered to have achieved HBeAg loss if the HBeAg measurement was reported as (a) 'NEGATIVE' or (b) a quantitative result was lower than the reported lower detection limit. This endpoint was measured in the participants with HBeAg positive CHB.
Quantitative Hepatitis B Surface Antigen Up to 276 Weeks Quantitative HBsAg assay is a diagnostic test for assessing the amount of the HBsAg in chronic hepatitis B participants. Last approved quantitative HBsAg measurement in the analyzed time window.
Number of Participants With Chronic Hepatitis B - Associated Clinical Endpoints- Liver Transplantation, Hepatocellular Carcinoma, and Liver Decompensation Up to 276 Weeks Number of clinical endpoints associated with CHB reported in the medical record, where data available, are reported. The clinical endpoints included liver transplantation, hepatocellular carcinoma, liver decompensation, development of cirrhosis (in patients without cirrhosis at baseline).
Percentage of Participants With Hepatitis B Surface Antigen Seroconversion Up to 276 Weeks Hepatitis B surface antigen (HBsAg) is a viral protein detectable in the blood in acute and chronic hepatitis B infection. A participant was considered to have achieved HBsAg seroconversion if (a) the participant achieved HBsAg clearance and (b) the last approved anti-HBs measurement in the analyzed time window was reported as i) 'POSITIVE' or (ii) quantitative result and was greater than or equal to the reported lower limit of detection.
Alanine Transaminase Ratio Over Time by Hepatitis B Virus e Antigen Status Up to 276 Weeks ALT ratio was calculated as serum ALT, divided by the upper limit of the normal range.
Number of Participants With Adverse Events and Serious Adverse Events Up to 276 Weeks An Adverse Events (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is a significant medical event in the investigator's judgment or requires intervention to prevent one or other of these outcomes.
Percentage of Participants With Normalization of Alanine Transaminase Up to 276 Weeks A participant was considered to have achieved normalization of alanine transaminase (ALT) if the ALT measurement was lower or equal to the upper limit of the normal range. Only patients with elevated ALT at baseline were included in any analyses where normalization of ALT was used as endpoint. It was analyzed as last serum ALT in the analyzed time window, divided by the upper limit of the normal range.
Number of Participants With Chronic Hepatitis B Associated Clinical Endpoints- Liver Cirrhosis Up to 276 Weeks Number of participants with clinical endpoints associated with CHB captured in the medical record, where data available, are reported. The clinical endpoints included development of cirrhosis (in participants without cirrhosis at baseline). The liver cirrhosis assessments were summarized from Week 12 to 3 years post-treatment.
Percentage of Participants With Suppression of Hepatitis B Virus Deoxyribonucleic Acid to <2,000 International Units Per Milliliter Up to 276 Weeks A participant was considered to have achieved suppression of Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) to \<2,000 International Units Per Milliliter (IU/mL) if the HBV DNA measurement is lower than 2,000 IU/mL.
Percentage of Participants With Hepatitis B Virus e Antigen Seroconversion and Hepatitis B Virus Deoxyribonucleic Acid <2000IU/mL in Hepatitis B Virus e Antigen Positive Participants Up to 276 Weeks A participant was considered to have achieved HBeAg seroconversion and suppression of HBV DNA to \<2,000 IU/mL if (a) the participant achieved HBeAg seroconversion and (b) the participant achieved suppression of HBV DNA to \<2,000 IU/mL. If a patient received NUCs after end of PEG IFN treatment, then a reported suppression of HBV DNA to \< 2,000 IU/mL during or after this NUC treatment were to be ignored, and HBV DNA ≥ 2,000 IU/mL was to be assigned. However, HBV DNA \< 2,000 IU/mL was not to be ignored, if the NUC treatment given parallel to PEG IFN was discontinued within the first 8 weeks after end of PEG IFN treatment and prior to the HBV DNA value concerned no further NUCs were administered.
Abbreviations for Seroconversion=sercnvrsn, Analysis A= AnalysA, and Analysis B= AnalysB, pt=post-treatment.Number of Participants With Serious Adverse Drug Reactions Up to 276 Weeks A serious adverse drug reactions (SADR) is any untoward medical occurrence suspected to be medicinal product-related that at any dose: Results in death, is life-threatening, NOTE: The term "life-threatening" in the definition of "serious" refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe. Requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or Is a congenital anomaly/birth defect.
Number of Deaths During Observation Period Up to 276 Weeks The clinical endpoint of deaths due to any cause during observation period is presented.
Trial Locations
- Locations (249)
Tiroler Landeskrankenanstalten Ges.M.B.H.; Klinische Abt. Für Gaströnterologie & Hepatologie
🇦🇹Innsbruck, Austria
Medizinische Universität Wien; Univ.Klinik für Innere Medizin III - Gastroenterologie & Hepatologie
🇦🇹Wien, Austria
The Liver Centre
🇧🇩Dhaka, Bangladesh
Cantonal Hospital Zenica; Department for Infective Diseases
🇧🇦Zenica, Bosnia and Herzegovina
Clinical Center Banja Luka; Department for Infective Diseases
🇧🇦Banja Luka, Bosnia and Herzegovina
Salmaniya Medical Complex; Gastroenterology
🇧🇭Manama, Bahrain
A.Ö. Krankenhaus Der Elisabethinen Linz; Iv. Med. Abtl.
🇦🇹Linz, Austria
Clinical Center Sarajevo; Gastroenterohepatology
🇧🇦Sarajevo, Bosnia and Herzegovina
Liver Clinic Lab-Aid Specialized Hospital
🇧🇩Dhaka, Bangladesh
University Clinical Center Tuzla; Clinic for Gastroenterology
🇧🇦Tuzla, Bosnia and Herzegovina
Mhat Sveta Marina; Clinic of Gastroenterology
🇧🇬Varna, Bulgaria
MHAT Tokuda Hospital Sofia; Department of Gastroenterology at Clinic of Internal Deseases
🇧🇬Sofia, Bulgaria
Yehia Elshazly Clinic for Hepatology and Gastroentrology
🇪🇬Cairo, Egypt
Dr.Nadia Elansary Clinic
🇪🇬Cairo, Egypt
Dr. Taher Elzanaty clinic
🇪🇬Giza, Egypt
Dr. Ahmed Monis Clinic
🇪🇬Giza, Egypt
Dr. Ibrahim Mostafa Clinic
🇪🇬Cairo, Egypt
Pai Clinic and Diagnostic Center
🇮🇳Pune, India
Mater Misericordiae University Hospital;Gastrointestinal Unit/Center for Liver Disease
🇮🇪Dublin, Ireland
St. James Hospital; Hepatology
🇮🇪Dublin, Ireland
King Abdullah University Hospital
🇯🇴Irbid, Jordan
Beirut Governmental University Hospital
🇱🇧Beirut, Lebanon
CHU Hassan 2; Service Gastro Enterologie Pr IBRAHIMI
🇲🇦Fes, Morocco
Centre Hospitalier Universitaire Ibn Sina; Service de Gastro-entérologie Essaid
🇲🇦Rabat, Morocco
Islamabad Specialist Clinic
🇵🇰Islamabad, Pakistan
Akbar Center
🇵🇰Karachi, Pakistan
Dow University of Health Sciences; Department of Medicine
🇵🇰Karachi, Pakistan
Kanaan Clinic
🇵🇰Lahore, Pakistan
Saeed Anwar Medical Centre
🇵🇰Peshawar, Pakistan
King Faisal Specialist Hospital & Research Centre; Oncology
🇸🇦Riyadh, Saudi Arabia
Rashid Hospital; Gastroenterology
🇦🇪Dubai, United Arab Emirates
Combined Military Hospital; Department of Medicine
🇵🇰Rawalpindi, Pakistan
Holy Family Hospital; Department of Medicine
🇵🇰Rawalpindi, Pakistan
Pomorskie Centrum Chorob Zakaznych i Gruzlicy
🇵🇱Gdansk, Poland
Specjalistyczny Szpital Wojewódzki im. Biegańskiego; Klinika Chorób Zakaźnych i Hepatologii UM
🇵🇱Łodz, Poland
Hospital Geral de Santo Antonio; Servico de Gastrenterologia
🇵🇹Porto, Portugal
Cantacuzino Clinical Hospital;Gastroenterology Department
🇷🇴Bucharest, Romania
Medical Uni of Bialystok; Infectious Diseases
🇵🇱Bialystok, Poland
Hospital For Infectious Diseases; Infectiology
🇵🇱Bydgoszcz, Poland
Inst. of Infectious & Parasitic Diseases; Clinic of Hepatology & Aquired Immunodeficiencies
🇵🇱Warszawa, Poland
Szpital Specjalistyczny; Oddzial Obserwacyjno - Zakayny
🇵🇱Chorzow, Poland
Krakowski Szpital Specjalistyczny im. Jana Pawla II; Oddzial Wirusowego Zapalenia Watroby
🇵🇱Krakow, Poland
Medical Uni of Lodz; Infectious Diseases
🇵🇱Lodz, Poland
Wojewodzki Szpital; Specjalistyczny Chorob Zakaznych
🇵🇱Wroclaw, Poland
Wojewódzki specjalistyczny szpital im. Bieganskiego; Oddział Obserwacyjno-Zakazny i Chorob Watroby
🇵🇱Lodz, Poland
NZOZ Lubuska Specjalistyczna Poradnia Chorob Watroby
🇵🇱Zielona Góra, Poland
Clinical Infectious Diseases Hospital Victor Babes
🇷🇴Craiova, Romania
Spitalul Clinic de Boli Infectioase si Tropicale Dr. Victor; INFECTIOUS DISEASE
🇷🇴Craiova, Romania
King Fahad University Hospital; Internal Medicine
🇸🇦Alkhobar, Saudi Arabia
Institutul De Boli Infectioase Matei Bals; Sectia Clinica II Boli Infectioase Adulti
🇷🇴Bucharest, Romania
The Hospital of Tropical and Infectious Disease Victor Babes
🇷🇴Bucharest, Romania
King Fahad Medical City; Gastroentrology
🇸🇦Riyadh, Saudi Arabia
North West Armed Forces Hospital; Internal Medicine
🇸🇦Tabuk, Saudi Arabia
Chiang Mai Uni Hospital; Faculty of Medicine
🇹🇭Chiang Mai, Thailand
Lkh-Univ. Klinikum Graz
🇦🇹Graz, Austria
The 1st Affiliated Hospital of Harbin Medical University
🇨🇳Harbin, China
Huashan Hospital Affiliated to Fudan University
🇨🇳Shanghai, China
Beijing You An Hospital; Digestive Dept
🇨🇳Beijing, China
West China Hospital, Sichuan University
🇨🇳Chengdu, China
Guangdong General Hospital
🇨🇳Guangzhou, China
Hangzhou Sixth People's Hospital
🇨🇳Hangzhou, China
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
🇨🇳Shanghai, China
The Second Affiliated Hospital of The Fourth Military Medical University (Tangdu Hospital)
🇨🇳Xi'an, China
Wilhelminenspital; Iv. Medizinische Abt.
🇦🇹Wien, Austria
University Clinical Center Tuzla; Clinic for Infective Diseases
🇧🇦Tuzla, Bosnia and Herzegovina
Jinan Infectious Diseases Hospital
🇨🇳Jinan, China
The 85th Hospital of P.L.A.
🇨🇳Shanghai, China
Peking University People's Hospital
🇨🇳Beijing, China
Shenzhen Donghu Hospital
🇨🇳Shen Zhen, China
The Third Hospital of Hebei Medical University
🇨🇳Shi Jiazhuang, China
Hopital Nord; Reseau Hepatologie Picardie
🇫🇷Amiens, France
Hotel Dieu; Medecine A
🇫🇷Angers, France
Hopital Avicenne; Unite D Hepatologie
🇫🇷Bobigny, France
Hopital Esquirol; Cons Externes
🇫🇷St Maurice, France
Hopital Nord; Medecine A
🇫🇷Amiens, France
Hopital Jean Verdier; Gastro Enterologie
🇫🇷Bondy, France
Ch Sud Francilien; Cons Gastro Enterologie
🇫🇷Corbeil Essonnes, France
Hopital Saint Jean; Hematologie
🇫🇷Perpignan, France
Tuen Mun Hospital; Medicine & Geriatrics
🇭🇰Tuen Mun, Hong Kong
Krishnai Clinic
🇮🇳Pune, India
Opp Jaslok Hospital
🇮🇳Mumbai, India
Institute of Digestive Diseases
🇮🇳Guwahati, India
Medipoint Clinic
🇮🇳Pune, India
Cipto Mangunkusumo General Hospital; Hematology & Oncology
🇮🇩Jakarta, Indonesia
Medistra Hospital; Hepatology
🇮🇩Jakarta, Indonesia
Medizinische Universitätsklinik; Med. Klinik Ii, Infektiologie
🇩🇪Wuerzburg, Germany
Klinikum Salzgitter-Lebenstedt Medizinische Klinik I
🇩🇪Salzgitter, Germany
Medanta -The Medicity; Department of Digestive and Hepatobiliary Sciences
🇮🇳Gurgaon, India
Prince Hamzeh Hospital; Internal Medicine
🇯🇴Amman, Jordan
Klinik Hati; Hepatology
🇮🇩Jakarta, Indonesia
Central Army Hospital Rspad Gatot Soebroto; Pulmonology
🇮🇩Jakarta, Indonesia
Clinical Center Skopje; Infectious Diseases
🇲🇰Skopje, Macedonia, The Former Yugoslav Republic of
Dres. Andreas Schaffert Andreas Trein und Edith Ißler u.w.
🇩🇪Stuttgart, Germany
Hasan Sadikin Hospital; Digestive Surgery
🇮🇩Bandung, Indonesia
Eulji General Hospital
🇰🇷Seoul, Korea, Republic of
Mitra International Jatinegara Hospital; Hepatology
🇮🇩Jakarta, Indonesia
Al-Bashir Hospital
🇯🇴Amman, Jordan
Inje University Pusan Paik Hospital
🇰🇷Busan, Korea, Republic of
Auckland Hospital; New Zealand Liver Transplant Unit
🇳🇿Auckland, New Zealand
PGI Cikini Hospital; Hepatology
🇮🇩Jakarta, Indonesia
Pundang Jesaeng General Hospital
🇰🇷Seoungnamsi, Korea, Republic of
Pusan University Hospital
🇰🇷Busan, Korea, Republic of
Korea Kuro Hospital; Internal Medicine
🇰🇷Seoul, Korea, Republic of
Chooncheon Sacred Heart Hospital
🇰🇷Chooncheon, Korea, Republic of
Ulsan University Hosiptal
🇰🇷Ulsan, Korea, Republic of
ChungAng University Hospital
🇰🇷Seoul, Korea, Republic of
Klinik Kimia Farma
🇮🇩Jakarta, Indonesia
Yonsei Uni College of Medicine, Severance Hospital; Internal Medicine Dept.
🇰🇷Seoul, Korea, Republic of
Inha University Hospital
🇰🇷Incheon, Korea, Republic of
Clinical Center Skopje; Gastroenterohepatology
🇲🇰Skopje, Macedonia, The Former Yugoslav Republic of
Pyungchon Sacred Heart Hospital
🇰🇷Anyang, Korea, Republic of
Chonbuk National Uni Hospital
🇰🇷Jeollabuk-do, Korea, Republic of
Kyungpook National Uni Hospital; Internal Medicine
🇰🇷Daegu, Korea, Republic of
Hepatitis Foundation
🇳🇿Whakatane, New Zealand
Sheikh Zayed Hospital; Department of Gastroentrology
🇵🇰Lahore, Pakistan
Centrum Medyczne
🇵🇱Lancut, Poland
Hospital de Sao Joao; Servico de Gastrenterologia
🇵🇹Porto, Portugal
Hull Royal Infirmary; Department Hepatology and Gastroenterology
🇬🇧Hull, United Kingdom
Allied Hospital; Department of Medicine
🇵🇰Faisalabad, Pakistan
Riyadh Military Hospital
🇸🇦Riyadh, Saudi Arabia
Songklanagarind Hospital; Division of Gastroenterology
🇹🇭Songkhla, Thailand
King'S College Hospital
🇬🇧London, United Kingdom
Siriraj Hospital
🇹🇭Bangkok, Thailand
Manchester Royal Infirmary; Department Of Medicine
🇬🇧Manchester, United Kingdom
Imperial College Healthcare Trust
🇬🇧London, United Kingdom
Beijing Ditan Hospital
🇨🇳Beijing, China
The Second Affiliated Hospital, Chongqing Medical University
🇨🇳Chongqing, China
The Eighth People's Hospital of Guangzhou
🇨🇳Guangzhou, China
Shanghai Public Health Clinical Center
🇨🇳Shanghai, China
Shengjing Hospital of China Medical University
🇨🇳ShenYang, China
Bethune International Peace Hospital of PLA
🇨🇳Shijiazhuang, China
Xinjiang Uygur Autonomous Region Hospital of Chinese Traditional Medicine
🇨🇳Urumqi, China
Indraprastha Apollo Hospitals
🇮🇳New Delhi, Delhi, India
Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo.
🇩🇪Ulm, Germany
Praxis Sabine Mauruschat
🇩🇪Wuppertal, Germany
Clinical Hospital Mostar; Department for Gastroenterology
🇧🇦Mostar, Bosnia and Herzegovina
Cantonal Hospital Bihac; Department for Infective Diseses
🇧🇦Bihac, Bosnia and Herzegovina
Beijing 302 Hospital; No. 2 Infectious Disease Section
🇨🇳Beijing, China
The First Affiliated Hospital of Wenzhou Medical College
🇨🇳Wenzhou, China
Dr.Mohamed Amr Affifi Clinic
🇪🇬Cairo, Egypt
Dr.Nabil Fawzy private clinic
🇪🇬Cairo, Egypt
Gamal Sheha Clinic
🇪🇬Mansoura, Egypt
Ch Du Pays D Aix; Gastro Enterologie
🇫🇷Aix En Provence, France
Ch Victor Dupouy; Hepato Gastro Medecine Interne
🇫🇷Argenteuil, France
Ch Victor Dupouy; Oncologie
🇫🇷Argenteuil, France
Ch Henri Duffaut;Gastro Enterologie
🇫🇷Avignon, France
Hopital Jean Minjoz; Hepatologie
🇫🇷Besancon, France
Hopital Saint Andre; Hepato-Gastro-Enterologie
🇫🇷Bordeaux, France
Ch Pierre Oudot; Gastro Enterologie
🇫🇷Bourgoin Jallieu, France
Hopital Cote De Nacre; Gastro Enterologie
🇫🇷Caen, France
Hopital Trousseau; Gastro Enterologie A Et B
🇫🇷Chambray Les Tours, France
Hopital Antoine Beclere; Hepatologie Gastro Enterologie
🇫🇷Clamart, France
Chu Estaing; Medecine Digestive
🇫🇷Clermont Ferrand, France
Hopital Beaujon; Gastro Enterologie 1
🇫🇷Clichy, France
Hopital Beaujon;Hepatologie
🇫🇷Clichy, France
Hopital Du Bocage; Gastro Enterologie
🇫🇷Dijon, France
Ch Laennec; Medecine IV
🇫🇷Creil, France
Ch Sud Francilien; Gastro Enterologie
🇫🇷Evry, France
Hopital Henri Mondor; Hepatologie Gastro Enterologie
🇫🇷Creteil, France
CABINET
🇫🇷Grasse, France
Ch De Lagny Sur Marne; Gastro Enterologie
🇫🇷Lagny Sur Marne, France
Hopital Albert Michallon; Gastro Enterologie
🇫🇷La Tronche, France
Ch Du Mans; Medecine Ii
🇫🇷Le Mans, France
Ch De Bicetre; Gastro Enterologie
🇫🇷Le Kremlin Bicetre, France
Hopital Claude Huriez;Gastro Enterologie
🇫🇷Lille, France
Hopital Dupuytren; Medecine Interne A
🇫🇷Limoges, France
Clinique De La Sauvegarde; Exploration Gastro Proctologie
🇫🇷Lyon, France
Hopital Hotel Dieu; Medecine Interne & D'Hepatologie
🇫🇷Lyon, France
Hopital De La Croix Rousse; Hepatologie Gastro Enterologie
🇫🇷Lyon, France
Fondation Hopital Saint Joseph; Gastro-Enterologie
🇫🇷Marseille, France
Hopital De La Conception; Rhumatologie
🇫🇷Marseille, France
Hopital De La Conception; Gastro Enterologie Endoscopie 2E Nord
🇫🇷Marseille, France
Hopital N D Bon Secours; Medecine B2
🇫🇷Metz, France
Hopital Jacques Monod; Gastro-Enterologie
🇫🇷Montivilliers, France
Ch De Montauban; Medecine Interne
🇫🇷Montauban, France
Cabinet Medical
🇫🇷Montpellier, France
Hopital Emile Muller; Gastro Enterologie
🇫🇷Mulhouse, France
Hopital Saint-Eloi; Hepatologie-Gastro-Enterologie
🇫🇷Montpellier, France
Hopital Hotel Dieu Et Hme; Hepatologie Gastro Enterologie
🇫🇷Nantes, France
Hopital Caremeau; Gastro Enterologie
🇫🇷Nimes, France
Cabinet
🇫🇷Nantes, France
Fondation Institut Arthur Vernes; Institut Arthur Vernes
🇫🇷Paris, France
Hopital La Source; Medecine H
🇫🇷Orleans, France
Ch Georges Renon; Maladies Infectieuses
🇫🇷Niort, France
Hopital Saint Antoine; Hepatologie-Gastr-Enterologie
🇫🇷Paris, France
Hopital Bichat Claude Bernard; Hepatologie Gastro Enterologie
🇫🇷Paris, France
CH Pitie Salpetriere; Hepathologie Gastro Enterologie
🇫🇷Paris, France
Hopital Du Haut-Leveque; Gastro-Enterologie
🇫🇷Pessac, France
Hopital Robert Debre; Gastro Enterologie
🇫🇷Reims, France
Hopital de Pontchaillou; Medicine Interne - Hepatologie
🇫🇷Rennes, France
Institut Arnault Tzanck; Medecine I Gastro Enterologie
🇫🇷Saint Laurent Du Var, France
Hopital Charles Nicolle; Gastro Enterologie
🇫🇷Rouen, France
Hopital Civil; Hepatologie-Gastro-Enterologie
🇫🇷Strasbourg, France
Cabinet Medical Gastro Enterologie
🇫🇷Toulon, France
Hopital Font Pre; Gastro Enterologie
🇫🇷Toulon, France
Hopital Purpan;Gastro Enterologie Hepatologie
🇫🇷Toulouse, France
Hopitaux de Brabois - Gastro-Entereologie
🇫🇷Vandoeuvre-les-nancy, France
Clinique Ambroise Pare; Medecine
🇫🇷Toulouse, France
Praxis Dr. med. Christine John
🇩🇪Berlin, Germany
Hopital Paul Brousse; Centre Hepatologie Biliaire
🇫🇷Villejuif, France
Charité Universitätsmedizin Berlin; Campus Mitte, Centrum 12, Medizinische Poliklinik
🇩🇪Berlin, Germany
überörtl.Gem.Praxis Dres. Stephan Dupke Axel Baumgarten
🇩🇪Berlin, Germany
Charité - Campus Benjamin Franklin; Zentrum fuer Innere Medizin, Med. Klinik I
🇩🇪Berlin, Germany
CAMPUS VIRCHOW-KLINIKUM; Charité Centrum 13; Med. Klinik Abt. Hepatologie u. Gastroenterologie
🇩🇪Berlin, Germany
Praxis Dr. Heyne
🇩🇪Berlin, Germany
Campus Virchow-Klinikum Charité Centrum 13; Medizinische Klinik; Abt.Hepatologie u.Gastroenterologie
🇩🇪Berlin, Germany
Dres. Jörg Gölz und Arend Moll
🇩🇪Berlin, Germany
Universitätsklinikum Klinik f. Gastroenterologie Hepatologie und Infektiologie
🇩🇪Düsseldorf, Germany
Universitätsklinikum Bonn Med. Klinik u. Poliklinik I
🇩🇪Bonn, Germany
Universitätsklinikum Erlangen; Medizinische Klinik 1
🇩🇪Erlangen, Germany
Universitaetsklinikum Essen, Innere Klinik und Poliklinik fuer Tumorforschung
🇩🇪Essen, Germany
Praxis PD Dr.med. Gerlinde Teuber
🇩🇪Frankfurt am Main, Germany
Universitätsklinikum Gießen und Marburg GmbH Standort Gießen Medizinische Klinik II
🇩🇪Giessen, Germany
Universitätsklinikum Freiburg Medizinische Klinik Innere Medizin I
🇩🇪Freiburg, Germany
Med. Versorgungszentrum ifi-Institut
🇩🇪Hamburg, Germany
Infektionsmedizinisches Centrum Hamburg ICH Grindel
🇩🇪Hamburg, Germany
St.Marien-Hospital Klinik Knappenstraße Klinik f.Gastroenterologie
🇩🇪Hamm, Germany
Medizinische Hochschule Zentrum Innere Medizin Abt.Gastroenterologie, Endokrinologie und Hepatologie
🇩🇪Hannover, Germany
Uni Heidelberg Med. Klinik; Innere Medizin IV
🇩🇪Heidelberg, Germany
Dres.Dietrich Hüppe Gisela Felten und Heinz Hartmann
🇩🇪Herne, Germany
Universitätsklinikum Jena; Klinik für Innere Medizin II
🇩🇪Jena, Germany
Universitätsklinikum Magdeburg Klinik für Gastroenterologie und Hepatologie
🇩🇪Magdeburg, Germany
Universitätsklinikum S.-H. Campus Kiel Klinik für Innere Medizin I Gastroenterologie Hepotologie
🇩🇪Kiel, Germany
Universitätsklinikum Schleswig-Holstein / Campus Lübeck, Med. Klinik I, Transplantationszentrum
🇩🇪Lübeck, Germany
Uniklinik Mainz; I. Medizinische Klinik
🇩🇪Mainz, Germany
Klinikum rechts der Isar der TU München; II. Medizinische Klinik & Poliklinik
🇩🇪München, Germany
Universitätsklinikum Münster Klinik und Poliklinik für Transplantationsmedizin
🇩🇪Münster, Germany
Dr.med.Heiner W.Busch und Stefan Christensen
🇩🇪Münster, Germany
St. Josefs Klinik; Medizinische Klinik
🇩🇪Offenburg, Germany
Santosa Bandung International Hospital; Hepatology
🇮🇩Bandung, Indonesia
Klinikum Nord Medizinische Klinik 6
🇩🇪Nürnberg, Germany
Sree Gokulam Medical College and Research Foundation
🇮🇳Trivandrum, India
Boromeus Hospital; Hepatology
🇮🇩Bandung, Indonesia
Bintaro International Hospital, Hepatology
🇮🇩Tangerang, Indonesia
Dr. Soetomo Hospital; Kidney and Hipertansion
🇮🇩Surabaya, Indonesia
Chungnam University Hospital
🇰🇷Daejeon, Korea, Republic of
Samsung Medical Centre; Division of Hematology/Oncology
🇰🇷Seoul, Korea, Republic of
American University of Beirut - Medical Center
🇱🇧Beirut, Lebanon
Hotel-Dieu de France Hospital; Gastroenterology
🇱🇧Beirut, Lebanon
Cabinet Privé Pr D Jamil
🇲🇦Casablanca, Morocco
Waikato Hospital; Gastroenterology
🇳🇿Hamilton, New Zealand
Medicare Clinics
🇵🇰Karachi, Pakistan
Hospital de Santa Maria; Servico de Gastrenterologia e Hepatologia
🇵🇹Lisboa, Portugal
Centralny Szpital Kliniczny MSWiA; Oddzial Chorob Wewnetrznych i Hepatologii
🇵🇱Warszawa, Poland
St. Georges Uni of London; Gastroenterology & Hepatology
🇬🇧London, United Kingdom
University College London; Hepatology
🇬🇧London, United Kingdom
The Royal London Hospital
🇬🇧London, United Kingdom
Dres.Bernd Möller und Renate Heyne
🇩🇪Berlin, Germany
Nanjing No.2 Hospital; Liver Disease Department
🇨🇳Nanjing, China